Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S M SwainR A Gams

Abstract

To assess whether dexrazoxane (DZR) given after a cumulative doxorubicin dose of 300 mg/m2 confers cardioprotection in patients with advanced breast cancer treated with fluorouracil, doxorubicin, and cyclophosphamide (FAC). In two multicenter studies (088001 and 088006), patients were randomized to receive FAC and placebo (PLA) versus FAC and DZR. After a protocol amendment, all patients received open-label DZR after they had reached a cumulative doxorubicin dose of 300 mg/m2. Two groups were compared: 99 patients randomized to the PLA arms before the amendment who received FAC and PLA for at least seven courses (PLA group), and 102 patients randomized to the PLA arms after the amendment who received FAC and PLA for six courses followed by open-label DZR (PLA/DZR group). The hazards ratio of PLA to PLA/DZR was 3.5 (95% confidence interval [CI], 2.2 to 5.7; P < .001, logrank and generalized Wilcoxon tests) for the doxorubicin dose at any cardiac event, ejection fraction changes, or congestive heart failure (CHF). The hazards ratio of PLA to PLA/DZR was 13.1 (95% CI, 3.7 to 46.0; P < .001, logrank and generalized Wilcoxon tests) for the doxorubicin dose at the development of CHF. The overall incidence of CHF in the PLA/DZR group ...Continue Reading

Citations

Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K Hellmann
May 11, 2005·Molecular Pharmacology·X XuD R Richardson
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin D FloydMichael C Perry
Oct 30, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Ei IkegamiShunichi Ogawa
Aug 19, 2009·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Ho Sup LeeYang Soo Kim
Feb 3, 2009·Cancer Chemotherapy and Pharmacology·Sabry M AttiaMohammed M Al-Harbi
Jun 17, 2011·The Cochrane Database of Systematic Reviews·Elvira C van DalenLeontien Cm Kremer
Mar 16, 2013·Medicinal Research Reviews·Filipa S CarvalhoPaulo J Oliveira
Sep 18, 2013·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Geeta GulatiTorbjørn Omland
Oct 5, 2013·Clinical Pharmacology and Therapeutics·P Vejpongsa, E T H Yeh
Sep 19, 2014·Current Opinion in Oncology·Manali BhaveSteven T Rosen
Dec 30, 2014·Frontiers in Oncology·Shuang Guo, Serena Wong
Oct 19, 2016·Journal of Cardiovascular Medicine·Pier P BassareoGiuseppe Mercuro
Jul 4, 2016·Medical Oncology·Ibrahim Fanous, Patrick Dillon
Jul 7, 2017·Expert Opinion on Drug Metabolism & Toxicology·Neha BansalSteven E Lipshultz
Nov 18, 2018·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Raymond Russell
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G WilliamsR Pazdur
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A SparanoW C Wood
Jun 28, 2005·Paediatric Drugs·Valeriano C SimbreSteven E Lipshultz
Oct 21, 2005·Basic & Clinical Pharmacology & Toxicology·Snezana K BjelogrlicSinisa Radulovic
Dec 15, 2005·British Journal of Haematology·Karlijn A WoutersSteven E Lipshultz
Aug 9, 2003·Expert Opinion on Drug Safety·Antonella PerottiLuca Gianni
Aug 12, 2008·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Franco TestoreGiuseppina Bosso
May 23, 2007·Expert Opinion on Pharmacotherapy·Elly BarrySteven E Lipshultz
Apr 7, 2007·American Journal of Clinical Oncology·Louis Wing-Cheong ChowBrian Hung-Hin Lang
Jun 13, 2006·Pediatric Blood & Cancer·David R Freyer
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Robin L Jones
Aug 9, 2012·Future Cardiology·Danielle HarakeSteven E Lipshultz
Dec 23, 2008·Breast Cancer Research and Treatment·Joseph Gligorov, Jean-Pierre Lotz
Feb 14, 2017·Clinical Cardiology·Marijana TadicOleksandr Danylenko
May 15, 2019·Current Opinion in Cardiology·Abdulrazzak ZarifaJuan Lopez-Mattei

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
S M SwainR A Gams
The New England Journal of Medicine
M MartinBreast Cancer International Research Group 001 Investigators
© 2021 Meta ULC. All rights reserved